729 results on '"Ayala, Rosa"'
Search Results
2. Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
3. Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT
4. A deep learning model for natural language querying in Cyber–Physical Systems
5. SI4IoT: A methodology based on models and services for the integration of IoT systems
6. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes
7. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
8. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia
9. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
10. A typical acute lymphoblastic leukemia JAK2 variant, R683G, causes an aggressive form of familial thrombocytosis when germline
11. Author Correction: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
12. Supplementary Data 1 from Short-Chain Fatty Acid Production by Gut Microbiota Predicts Treatment Response in Multiple Myeloma
13. Data from Short-Chain Fatty Acid Production by Gut Microbiota Predicts Treatment Response in Multiple Myeloma
14. Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
15. Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial
16. Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges.
17. The prognostic impact of non‐driver gene mutations and variant allele frequency in primary myelofibrosis.
18. Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero Trial
19. Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
20. MPL S505C enhances driver mutations at W515 in essential thrombocythemia
21. A model-driven engineering approach for the service integration of IoT systems
22. Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia
23. Postfledging movements in birds: Do tit families track environmental phenology?
24. Integrating AIPSS‐MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis.
25. Should we move to a genomic classification of neutrophilic myeloid neoplasms?
26. P-473 Real-world evidence of statins and oral antidiabetics for multiple myeloma
27. POSTER: MPN-381 BMS-986158, a Potent Bromodomain and Extraterminal Domain Inhibitor (BETi), as Monotherapy and in Combination With Ruxolitinib (RUX) or Fedratinib (FED) in Intermediate-Risk or High-Risk Myelofibrosis (MF): Results From a Phase I/II Study
28. MPN-381 BMS-986158, a Potent Bromodomain and Extraterminal Domain Inhibitor (BETi), as Monotherapy and in Combination With Ruxolitinib (RUX) or Fedratinib (FED) in Intermediate-Risk or High-Risk Myelofibrosis (MF): Results From a Phase I/II Study
29. P-062 Real-world evidence of bisphosphonates and denosumab for multiple myeloma
30. Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure
31. Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
32. P1100: PET INTERIM RESULTS COULD PROMPTLY SELECT FOLLICULAR LYMPHOMA PATIENTS IN NEED OF MAINTENANCE THERAPY. POTENTIAL ADDITIONAL VALUE OF CFDNA.
33. P948: REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA
34. S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY
35. Multidisciplinary management in chronic myeloid leukemia improves cardiovascular risk measured by SCORE
36. Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?
37. Impact of IPSS-M implementation in real-life clinical practice
38. Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study
39. Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis
40. Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype
41. MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia
42. Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
43. The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients
44. Semantic Matching of Components at Run-Time in Distributed Environments
45. Review of Artificial Intelligence Techniques in Green/Smart Buildings
46. Aprendizaje cooperativo, trascendiendo el aula convencional
47. Global real-life analysis of survival and usage of therapies in multiple myeloma
48. Clinical application of molecular diagnostics in myeloid disorders: recommendations for implementing a common strategy in Spanish centers
49. Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma
50. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.